Drug Trial Radar · NCT06062875
Effects of TNF Blockade on Human BPH/LUTS
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jan 24, 2024
Primary completion
Apr 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- Endeavor HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Oct 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH/LUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify genetic predictors to stratify patients with differential response to TNF-antagonist therapy.
Conditions
- Benign Prostatic Hyperplasia (BPH)
Interventions
AdalimumabDrug
Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- International Prostate Symptom ScoreTime frame: The past 30 days
- Safety as measured by Clavien-Dindo grading systemTime frame: Through study completion (Week 24)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NorthShore University HealthSystem
Glenview, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.